Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults

NCT03158038 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT03158038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03158038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults
Lead sponsor
MedImmune LLC
Phase
Phase 4
Overall status
Completed
Start date
May 30, 2017
Completion date
December 14, 2017
Enrollment
300 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, influenza